| Multiple Sclerosis |
1 |
1 |
| Immunization |
0 |
0.77 |
| COVID-19 |
0 |
0.99 |
| COVID-19 Vaccine |
0 |
0.61 |
| Vaccines |
0 |
0.53 |
| Fellowship |
0 |
0.46 |
| NHS |
0 |
0.22 |
| Antiviral Agents |
0 |
0.15 |
| Central Nervous System |
0 |
0.15 |
| Clinical Guidelines |
0 |
0.15 |
| Clinical Research |
0 |
0.15 |
| Disease-Modifying Therapy |
0 |
0.15 |
| Health Care Services |
0 |
0.15 |
| Multiple Sclerosis Relapse |
0 |
0.15 |
| Multiple Sclerosis Treatment |
0 |
0.15 |
| New York |
0 |
0.15 |
| Pandemic |
0 |
0.15 |
| Salary and Compensation |
0 |
0.15 |
| Healthcare and Medical Technology |
0 |
0.04 |
| Revenue and Practice Management |
0 |
0.04 |